<?xml version="1.0" encoding="UTF-8"?>
<p>Exclusion criteria included current or a history of decompensated liver disease, active tuberculosis, positive hepatitis B surface antigen, hepatocellular carcinoma, prior DAA therapy (prior interferon‐based therapy allowed), active drug or alcohol abuse, and pregnancy. Individuals with human immunodeficiency virus (HIV) co‐infection were eligible for the study if the participant was on stable antiretroviral therapy compatible with LDV/SOF and the HIV RNA level was &lt; 200 copies/mL with a clusters of differentiation 4 (CD4) + T‐cell count ≥ 100 cells/µL.</p>
